• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 3 - The CoMMpass Study

Article

Ms Young addresses MMRF's CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years.

Ms Young addresses MMRF’s CoMMpass study, a longitudinal study that is following 1000 patients who have been newly diagnosed with multiple myeloma, from initial diagnosis over a period of at least 5 years. MMRF hopes the CoMMpass study will help researchers and providers better understand the natural history of the disease and “give clues” in terms of how best to treat patients using precision medicine approaches.

Dr Goldberg cautions that getting any early diagnosis can sometimes be problematic in determining whether a patient should start treatment. He also comments on existing and emerging agents for treatment of multiple myeloma.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.